Clearside Biomedical, Inc. (CLSD) Insider Daniel H. White Sells 8,000 Shares
Clearside Biomedical, Inc. (NASDAQ:CLSD) insider Daniel H. White sold 8,000 shares of the company’s stock in a transaction dated Thursday, October 19th. The shares were sold at an average price of $7.82, for a total transaction of $62,560.00. Following the completion of the transaction, the insider now owns 477,935 shares in the company, valued at $3,737,451.70. The transaction was disclosed in a filing with the SEC, which is available at this link.
Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up 0.38% during trading on Monday, reaching $7.93. The company’s stock had a trading volume of 6,464 shares. Clearside Biomedical, Inc. has a 52-week low of $5.44 and a 52-week high of $24.73. The stock’s 50-day moving average is $8.02 and its 200 day moving average is $8.02. The firm’s market capitalization is $200.91 million.
Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative net margin of 27,225.52% and a negative return on equity of 65.78%. The company had revenue of $0.13 million during the quarter. On average, analysts predict that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, August 11th. ValuEngine lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. Finally, TheStreet downgraded shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. Clearside Biomedical currently has an average rating of “Buy” and an average price target of $19.00.
Hedge funds have recently modified their holdings of the stock. Nationwide Fund Advisors increased its position in Clearside Biomedical by 118.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after buying an additional 6,343 shares during the period. Citadel Advisors LLC bought a new position in Clearside Biomedical in the 2nd quarter worth approximately $117,000. Parametric Portfolio Associates LLC bought a new position in Clearside Biomedical in the 2nd quarter worth approximately $122,000. ProShare Advisors LLC increased its position in Clearside Biomedical by 4.0% in the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after buying an additional 563 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in Clearside Biomedical in the 2nd quarter worth approximately $137,000. 52.45% of the stock is currently owned by institutional investors and hedge funds.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.